Conversely, prostate cancer patients without the TMPRSS2–ERG fusion gene may be better suited for therapies that target IGFs and Jak-Stat signalling, in which IGF signalling can be targeted through the use of tyrosine kinase inhibitors or monoclonal antibodies. The gene discussed is IGF1; the disease is prostate carcinoma.